DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocristals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal …). Our recent relocation to new facilities allowed us increasing our capacities for new projects and clients.